Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience

BACKGROUND: Thymic carcinoma (TC) is a rare aggressive tumour. Median survival with current treatments is only 2 years. Sunitinib is a multi-targeted tyrosine kinase inhibitor that has shown benefit in various other cancers. METHODS: Laboratory analyses of snap-frozen tumour tissues were performed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ströbel, P, Bargou, R, Wolff, A, Spitzer, D, Manegold, C, Dimitrakopoulou-Strauss, A, Strauss, L, Sauer, C, Mayer, F, Hohenberger, P, Marx, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906735/
https://www.ncbi.nlm.nih.gov/pubmed/20571495
http://dx.doi.org/10.1038/sj.bjc.6605740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906735/
https://www.ncbi.nlm.nih.gov/pubmed/20571495
http://dx.doi.org/10.1038/sj.bjc.6605740

Ejemplares similares